Thomas Kelly Jr
Title | Professor |
---|
Institution | University of Arkansas for Medical Sciences |
---|
Department | Pathology, College of Medicine |
---|
Division | Pathology Academic |
---|
Address | 318 Cancer Institute 200 South Cedar Mail Slot # 845 Little Rock AR 72202
|
---|
Phone | 501-686-6401 |
---|
vCard | Download vCard |
---|
|
|
|
Overview We are defining the mechanisms of cross-talk between activated fibroblasts and tumor associated macrophages that results in facilitation of breast cancer growth and progression that ultimately kills people with breast cancer. Specifically, we are investigating if activated fibroblasts are capable of converting immune activating macrophages (M1) to immune suppressive macrophages (M2). We are also investigating if immune suppressive macrophages can cause fibroblast activation. Steven R. Post and I have shown that SR-A mediated adhesion of macrophages to modified collagen results in PGE2 production and this PGE2 feeds back onto the macrophages and modulates cytokine production towards an M2 phenotype as evidenced by decreased TNF-alpha and increased IL-10 production (Nikolic et al, 2015, J. Leukocyte Biol. Feb 25. pii: jlb.2A1014-471RR. [Epub ahead of print]). We are currently looking to determine if adhesion of macrophages to FAP-modified collagen also promotes the M2 phenotype. I am an experienced PI with a broad background in cellular biology, and since 1992, I have focused my research on two matrix degrading enzymes—fibroblast activation protein-a (FAP) and heparanase—and their relationship to breast cancer. For over 20 years, I have led an independent research group that studies mechanisms of breast cancer metastasis that has been continuously funded by DoD-BCRP, NIH, and Industry grants and contracts. As a result, I am experienced in successfully administering research projects (e.g., staffing, research protections and budget) and collaborating with both basic and clinical scientists. My research has been published in prestigious cancer journals, such as Cancer Research and Blood. Through this research, my team and I have developed extensive experience with FAP biology in breast cancer.
Affiliation American Society for Cell Biology American Association for Cancer Research Metastasis Research Society
Research R25CA250979 (KELLY, THOMAS J)Sep 1, 2020 - Aug 31, 2025 NIH/Nat. Cancer Institute Partnership in Cancer Research (PCAR) Role: Principal Investigator |
| R21CA230059 (GALANZHA, EKATERINA I.)Sep 11, 2018 - Aug 31, 2020 NIH Lymph liquid biopsy in cancer Role: Co-Investigator |
| R21CA185691 (POST, STEVEN R)Dec 1, 2015 - Nov 30, 2018 NIH/National Institutes of Health Fibroblast-macrophage interactions induce a tumor-promoting microenvironment Role: Co-Principal Investigator |
| R01EB017217 (ZHAROV, VLADIMIR P)Jun 16, 2014 - May 31, 2019 NIH Photoswitchable nanoprobes for in vivo flow cytometry Role: Co-Investigator |
| R21CA139373 (ZHAROV, VLADIMIR P)May 17, 2009 - Apr 30, 2012 NIH In vivo molecular laser detection and treatment of circulating cancer stem cells Role: Co-Investigator |
| W81XWH-08-1-0589 (KELLY JR, THOMAS J)Sep 2, 2008 - Oct 1, 2011 US Department of the Army Fibroblast activation protein-alpha, a serine protease that facilitates metastasis by modification of diverse microenvironments Role: Principal Investigator |
| W81XWH-08-1-0589 W91ZSQ7343N640 (KELLY JR, THOMAS J)Sep 2, 2008 - Oct 1, 2011 US Department of the Army Fibroblast activation protein-alpha, a serine protease that facilitates metastasis by modification of diverse microenvironments Role: Principal Investigator |
| W81XWH (WARE, JERRY)Sep 1, 2008 - Aug 31, 2011 US Department of the Army Platelet glycoprotein Ib-IX and malignancy Role: Principal Investigator |
| CRA-DASH (KELLY JR, THOMAS J)Jun 29, 2007 - Jun 28, 2008 Ferring Research Limited Anti-tumor effects of inhibitors of fibroblast activation protein-alpha and other dipeptidyl peptidase and structural homologs (DASH) proteases Role: Principal Investigator |
| R01CA103054 (KELLY JR, THOMAS J)Apr 1, 2006 - Jun 30, 2009 NIH/Nat. Cancer Institute - Pass Through: University of Alabama at Birmingham Role of heparanase in osteolytic bone metastasis Role: Principal Investigator |
| 28913 ActivX-Kyorin SRA (KELLY JR, THOMAS J)Mar 10, 2005 - Mar 9, 2006 ActivX Biosciences, Inc Suppressing Breast Cancer Tumor Growth with Inhibitor-a Role: Principal Investigator |
| 28913ActivX-KyorinSRA (KELLY JR, THOMAS J)Mar 10, 2005 - Mar 9, 2006 ActivX Biosciences, Inc Suppressing Breast Cancer Tumor Growth with Inhibitor-a Role: Principal Investigator |
| R25CA049425 (KELLY JR, THOMAS J)Sep 30, 1989 - Jun 30, 2006 NIH/Nat. Cancer Institute Student Partners in Cancer Research and Education Role: Principal Investigator |
| R25CA49425 (KELLY JR, THOMAS J)Sep 30, 1989 - Jun 30, 2006 NIH/Nat. Cancer Institute Student Partners in Cancer Research and Education Role: Principal Investigator |
Bibliographic The links below are provided by the researcher to provide access to external online bibliographies that they keep independently from the Profiles System.
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
Faculty can login to make corrections and additions.
Don't see publications published under other names? Login to add alternative names.
-
Boyanton BL, Zarate YA, Broadfoot BG, Kelly T, Crawford BD. NR3C2 microdeletions-an underrecognized cause of pseudohypoaldosteronism type 1A: a case report and literature review. Lab Med. 2024 Sep 04; 55(5):640-644. PMID: 38493321.
-
Ferdous KU, Tesfay MZ, Cios A, Shelton RS, Hartupee C, Urbaniak A, Chamcheu JC, Mavros MN, Giorgakis E, Mustafa B, Simoes CC, Miousse IR, Basnakian AG, Moaven O, Post SR, Cannon MJ, Kelly T, Nagalo BM. Enhancing Neoadjuvant Virotherapy's Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer. Biomedicines. 2024 Jul 18; 12(7). PMID: 39062169.
-
Chen J, Lin Z, Fan J, Monzavi-Karbassi B, Kelly T, Post SR, Dai L, Qin Z. Identification of new microtubule small-molecule inhibitors and microtubule-associated genes against triple negative breast cancer. Am J Cancer Res. 2024; 14(4):1545-1560. PMID: 38726264.
-
Monzavi-Karbassi B, Kelly T, Post SR. The Tumor Microenvironment and Immune Response in Breast Cancer. Int J Mol Sci. 2024 Jan 11; 25(2). PMID: 38255987.
-
Marin LP, Presley JH, Noori K, McKinstry D, Dawson B, Sexton K, Peterson E, Harrington SE, Gardner JM, Nagalo BM, Montzavi-Karbassi B, Post SR, Nicholas RW, Kelly T. Partnership in Cancer Research (PCAR) Program Increases Medical Student Knowledge and Confidence to Perform Cancer Research. J Cancer Educ. 2024 Apr; 39(2):111-117. PMID: 37957501.
-
Mu L, Liu X, Yu H, Vickstrom CR, Friedman V, Kelly TJ, Hu Y, Su W, Liu S, Mantsch JR, Liu QS. cAMP-mediated upregulation of HCN channels in VTA dopamine neurons promotes cocaine reinforcement. Mol Psychiatry. 2023 Sep; 28(9):3930-3942. PMID: 37845497.
-
Kelly TJ, Bonniwell EM, Mu L, Liu X, Hu Y, Friedman V, Yu H, Su W, McCorvy JD, Liu QS. Psilocybin analog 4-OH-DiPT enhances fear extinction and GABAergic inhibition of principal neurons in the basolateral amygdala. Neuropsychopharmacology. 2024 Apr; 49(5):854-863. PMID: 37752222.
-
Nounamo B, Jousheghany F, Siegel ER, Post SR, Kelly T, Ferrone S, Kieber-Emmons T, Monzavi-Karbassi B. VT68.2: An Antibody to Chondroitin Sulfate Proteoglycan 4 (CSPG4) Displays Reactivity against a Tumor-Associated Carbohydrate Antigen. Int J Mol Sci. 2023 Jan 28; 24(3). PMID: 36768830.
-
Zhang Y, Gabere M, Taylor MA, Simoes CC, Dumbauld C, Barro O, Tesfay MZ, Graham AL, Ferdous KU, Savenka AV, Chamcheu JC, Washam CL, Alkam D, Gies A, Byrum SD, Conti M, Post SR, Kelly T, Borad MJ, Cannon MJ, Basnakian A, Nagalo BM. Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy. Front Oncol. 2022; 12:1042250. PMID: 36457491.
-
Liu X, Yu H, Chen B, Friedman V, Mu L, Kelly TJ, Ruiz-P?rez G, Zhao L, Bai X, Hillard CJ, Liu QS. CB2 Agonist GW842166x Protected against 6-OHDA-Induced Anxiogenic- and Depressive-Related Behaviors in Mice. Biomedicines. 2022 Jul 22; 10(8). PMID: 35892676.
-
Yu H, Liu X, Chen B, Vickstrom CR, Friedman V, Kelly TJ, Bai X, Zhao L, Hillard CJ, Liu QS. The Neuroprotective Effects of the CB2 Agonist GW842166x in the 6-OHDA Mouse Model of Parkinson's Disease. Cells. 2021 12 16; 10(12). PMID: 34944056.
-
Mu L, Liu X, Yu H, Hu M, Friedman V, Kelly TJ, Zhao L, Liu QS. Ibudilast attenuates cocaine self-administration and prime- and cue-induced reinstatement of cocaine seeking in rats. Neuropharmacology. 2021 12 15; 201:108830. PMID: 34626665.
-
Royse AG, Bellomo R, Royse CF, Clarke-Errey S, Boggett S, Kelly T, Paterson HS. Radial Artery vs Bilateral Mammary Composite Y Coronary Artery Grafting: 15-Year Outcomes. Ann Thorac Surg. 2021 06; 111(6):1945-1953. PMID: 33069678.
-
Zhang H, Ramsey A, Xiao Y, Karki U, Xie JY, Xu J, Kelly T, Ono S, Zhou GL. Dynamic Phosphorylation and Dephosphorylation of Cyclase-Associated Protein 1 by Antagonistic Signaling through Cyclin-Dependent Kinase 5 and cAMP Are Critical for the Protein Functions in Actin Filament Disassembly and Cell Adhesion. Mol Cell Biol. 2020 01 30; 40(4). PMID: 31791978.
-
Wu H, Hasan R, Zhang H, Gray J, Williams D, Miller M, Allen F, Lee V, Kelly T, Zhou GL. Phosphorylation Regulates CAP1 (Cyclase-Associated Protein 1) Functions in the Motility and Invasion of Pancreatic Cancer Cells. Sci Rep. 2019 03 20; 9(1):4925. PMID: 30894654.
-
Holthoff ER, Byrum SD, Mackintosh SG, Kelly T, Tackett AJ, Quick CM, Post SR. Vulvar squamous cell carcinoma aggressiveness is associated with differential expression of collagen and STAT1. Clin Proteomics. 2017; 14:40. PMID: 29225558.
-
Holthoff ER, Spencer H, Kelly T, Post SR, Quick CM. Pathologic features of aggressive vulvar carcinoma are associated with epithelial-mesenchymal transition. Hum Pathol. 2016 10; 56:22-30. PMID: 27327194.
-
Mazur A, Holthoff E, Vadali S, Kelly T, Post SR. Cleavage of Type I Collagen by Fibroblast Activation Protein-a Enhances Class A Scavenger Receptor Mediated Macrophage Adhesion. PLoS One. 2016; 11(3):e0150287. PMID: 26934296.
-
Jeffus SK, Gehlot A, Holthoff E, Stone R, Spencer H, Kelly T, Post SR, Quick CM. A fibromyxoid stromal response is associated with an infiltrative tumor morphology, perineural invasion, and lymph node metastasis in squamous cell carcinoma of the vulva. Am J Surg Pathol. 2015 Sep; 39(9):1226-33. PMID: 26274029.
-
Holthoff ER, Jeffus SK, Gehlot A, Stone R, Erickson SW, Kelly T, Quick CM, Post SR. Perineural Invasion Is an Independent Pathologic Indicator of Recurrence in Vulvar Squamous Cell Carcinoma. Am J Surg Pathol. 2015 Aug; 39(8):1070-4. PMID: 25786085.
-
Nikolic DM, Vadali S, He B, Ware J, Kelly T, Post SR. Prostaglandins produced during class A scavenger receptor-mediated macrophage adhesion differentially regulate cytokine production. J Leukoc Biol. 2015 May; 97(5):901-908. PMID: 25717147.
-
Rahal OM, Pabona JM, Kelly T, Huang Y, Hennings LJ, Prior RL, Al-Dwairi A, Simmen FA, Simmen RC. Suppression of Wnt1-induced mammary tumor growth and lower serum insulin in offspring exposed to maternal blueberry diet suggest early dietary influence on developmental programming. Carcinogenesis. 2013 Feb; 34(2):464-74. PMID: 23144318.
-
Kelly T, Huang Y, Simms AE, Mazur A. Fibroblast activation protein-a: a key modulator of the microenvironment in multiple pathologies. Int Rev Cell Mol Biol. 2012; 297:83-116. PMID: 22608558.
-
Huang Y, Simms AE, Mazur A, Wang S, Le?n NR, Jones B, Aziz N, Kelly T. Fibroblast activation protein-a promotes tumor growth and invasion of breast cancer cells through non-enzymatic functions. Clin Exp Metastasis. 2011 Aug; 28(6):567-79. PMID: 21604185.
-
Sharma SG, Gokden M, McKenney JK, Phan DC, Cox RM, Kelly T, Gokden N. The utility of PAX-2 and renal cell carcinoma marker immunohistochemistry in distinguishing papillary renal cell carcinoma from nonrenal cell neoplasms with papillary features. Appl Immunohistochem Mol Morphol. 2010 Dec; 18(6):494-8. PMID: 21102195.
-
Monzavi-Karbassi B, Hine RJ, Stanley JS, Ramani VP, Carcel-Trullols J, Whitehead TL, Kelly T, Siegel ER, Artaud C, Shaaf S, Saha R, Jousheghany F, Henry-Tillman R, Kieber-Emmons T. Fructose as a carbon source induces an aggressive phenotype in MDA-MB-468 breast tumor cells. Int J Oncol. 2010 Sep; 37(3):615-22. PMID: 20664930.
-
Kelly T, Suva LJ, Nicks KM, MacLeod V, Sanderson RD. Tumor-derived syndecan-1 mediates distal cross-talk with bone that enhances osteoclastogenesis. J Bone Miner Res. 2010 Jun; 25(6):1295-304. PMID: 20200931.
-
Galanzha EI, Shashkov EV, Kelly T, Kim JW, Yang L, Zharov VP. In vivo magnetic enrichment and multiplex photoacoustic detection of circulating tumour cells. Nat Nanotechnol. 2009 Dec; 4(12):855-60. PMID: 19915570.
-
Naito A, Cook CC, Mizumachi T, Wang M, Xie CH, Evans TT, Kelly T, Higuchi M. Progressive tumor features accompany epithelial-mesenchymal transition induced in mitochondrial DNA-depleted cells. Cancer Sci. 2008 Aug; 99(8):1584-8. PMID: 18754870.
-
Mueller S, Artym V, and Kelly. T. The Cancer Degradome - Proteases in Cancer Biology, Eds: Ed. D. Edwards, G. Hoyer-Hansen, F. Blasi, and B. F. Sloane. Invadopodia: Interface for invasion. 2008; 403-431.
-
Xu YJ, Davenport M, Kelly TJ. Two-stage mechanism for activation of the DNA replication checkpoint kinase Cds1 in fission yeast. Genes Dev. 2006 Apr 15; 20(8):990-1003. PMID: 16618806.
-
Kelly T, Coleman EA, Fifer EK, Burns ER, Orr C, Nicholas RW. Partners in research: benefits of a summer research program. J Cancer Educ. 2006; 21(4):243-7. PMID: 17542717.
-
Sanderson RD, Yang Y, Kelly T, MacLeod V, Dai Y, Theus A. Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: growth regulation and the prospect of new cancer therapies. J Cell Biochem. 2005 Dec 01; 96(5):897-905. PMID: 16149080.
-
Monzavi-Karbassi B, Whitehead TL, Jousheghany F, Artaud C, Hennings L, Shaaf S, Slaughter A, Korourian S, Kelly T, Blaszczyk-Thurin M, Kieber-Emmons T. Deficiency in surface expression of E-selectin ligand promotes lung colonization in a mouse model of breast cancer. Int J Cancer. 2005 Nov 10; 117(3):398-408. PMID: 15906360.
-
Zharov VP, Galitovskaya EN, Johnson C, Kelly T. Synergistic enhancement of selective nanophotothermolysis with gold nanoclusters: potential for cancer therapy. Lasers Surg Med. 2005 Sep; 37(3):219-26. PMID: 16175635.
-
Kelly T, Suva LJ, Huang Y, Macleod V, Miao HQ, Walker RC, Sanderson RD. Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases. Cancer Res. 2005 Jul 01; 65(13):5778-84. PMID: 15994953.
-
Kelly T. Fibroblast activation protein-alpha and dipeptidyl peptidase IV (CD26): cell-surface proteases that activate cell signaling and are potential targets for cancer therapy. Drug Resist Updat. 2005 Feb-Apr; 8(1-2):51-8. PMID: 15939342.
-
Yang Y, Macleod V, Bendre M, Huang Y, Theus AM, Miao HQ, Kussie P, Yaccoby S, Epstein J, Suva LJ, Kelly T, Sanderson RD. Heparanase promotes the spontaneous metastasis of myeloma cells to bone. Blood. 2005 Feb 01; 105(3):1303-9. PMID: 15471949.
-
Sanderson RD, Yang Y, Suva LJ, Kelly T. Heparan sulfate proteoglycans and heparanase--partners in osteolytic tumor growth and metastasis. Matrix Biol. 2004 Oct; 23(6):341-52. PMID: 15533755.
-
Huang Y, Wang S, Kelly T. Seprase promotes rapid tumor growth and increased microvessel density in a mouse model of human breast cancer. Cancer Res. 2004 Apr 15; 64(8):2712-6. PMID: 15087384.
-
Kelly T, Miao HQ, Yang Y, Navarro E, Kussie P, Huang Y, MacLeod V, Casciano J, Joseph L, Zhan F, Zangari M, Barlogie B, Shaughnessy J, Sanderson RD. High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Res. 2003 Dec 15; 63(24):8749-56. PMID: 14695190.
-
Chen WT, Kelly T. Seprase complexes in cellular invasiveness. Cancer Metastasis Rev. 2003 Jun-Sep; 22(2-3):259-69. PMID: 12785000.
-
Gong M, Wilson M, Kelly T, Su W, Dressman J, Kincer J, Matveev SV, Guo L, Guerin T, Li XA, Zhu W, Uittenbogaard A, Smart EJ. HDL-associated estradiol stimulates endothelial NO synthase and vasodilation in an SR-BI-dependent manner. J Clin Invest. 2003 May; 111(10):1579-87. PMID: 12750408.
-
Chen WT, Kelly T, Ghersi G. DPPIV, seprase, and related serine peptidases in multiple cellular functions. Curr Top Dev Biol. 2003; 54:207-32. PMID: 12696751.
-
Goodman JD, Rozypal TL, Kelly T. Seprase, a membrane-bound protease, alleviates the serum growth requirement of human breast cancer cells. Clin Exp Metastasis. 2003; 20(5):459-70. PMID: 14524536.
-
Hovdenak N, Wang J, Sung CC, Kelly T, Fajardo LF, Hauer-Jensen M. Clinical significance of increased gelatinolytic activity in the rectal mucosa during external beam radiation therapy of prostate cancer. Int J Radiat Oncol Biol Phys. 2002 Jul 15; 53(4):919-27. PMID: 12095558.
-
Kelly T, B?rset M, Abe E, Gaddy-Kurten D, Sanderson RD. Matrix metalloproteinases in multiple myeloma. Leuk Lymphoma. 2000 Apr; 37(3-4):273-81. PMID: 10752979.
-
Kelly T. Evaluation of seprase activity. Clin Exp Metastasis. 1999 Feb; 17(1):57-62. PMID: 10390148.
-
Kaushal GP, Xiong X, Athota AB, Rozypal TL, Sanderson RD, Kelly T. Syndecan-1 expression suppresses the level of myeloma matrix metalloproteinase-9. Br J Haematol. 1999 Feb; 104(2):365-73. PMID: 10050721.
-
Kelly T, Kechelava S, Rozypal TL, West KW, Korourian S. Seprase, a membrane-bound protease, is overexpressed by invasive ductal carcinoma cells of human breast cancers. Mod Pathol. 1998 Sep; 11(9):855-63. PMID: 9758365.
-
Kelly T, Yan Y, Osborne RL, Athota AB, Rozypal TL, Colclasure JC, Chu WS. Proteolysis of extracellular matrix by invadopodia facilitates human breast cancer cell invasion and is mediated by matrix metalloproteinases. Clin Exp Metastasis. 1998 Aug; 16(6):501-12. PMID: 9872598.
-
Dhodapkar MV, Kelly T, Theus A, Athota AB, Barlogie B, Sanderson RD. Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma. Br J Haematol. 1997 Nov; 99(2):368-71. PMID: 9375756.
-
Monsky WL, Lin CY, Aoyama A, Kelly T, Akiyama SK, Mueller SC, Chen WT. A potential marker protease of invasiveness, seprase, is localized on invadopodia of human malignant melanoma cells. Cancer Res. 1994 Nov 01; 54(21):5702-10. PMID: 7923219.
-
Kelly T, Mueller SC, Yeh Y, Chen WT. Invadopodia promote proteolysis of a wide variety of extracellular matrix proteins. J Cell Physiol. 1994 Feb; 158(2):299-308. PMID: 8106567.
-
Chen WT, Lee CC, Goldstein L, Bernier S, Liu CH, Lin CY, Yeh Y, Monsky WL, Kelly T, Dai M, et al. Membrane proteases as potential diagnostic and therapeutic targets for breast malignancy. Breast Cancer Res Treat. 1994; 31(2-3):217-26. PMID: 7881100.
-
Monsky WL, Kelly T, Lin CY, Yeh Y, Stetler-Stevenson WG, Mueller SC, Chen WT. Binding and localization of M(r) 72,000 matrix metalloproteinase at cell surface invadopodia. Cancer Res. 1993 Jul 01; 53(13):3159-64. PMID: 8391388.
-
Mueller SC, Kelly T, Dai MZ, Dai HN, Chen WT. Dynamic cytoskeleton-integrin associations induced by cell binding to immobilized fibronectin. J Cell Biol. 1989 Dec; 109(6 Pt 2):3455-64. PMID: 2513332.
-
Kelly, T. PhD Dissertation. 1988.
-
Burridge K, Fath K, Kelly T, Nuckolls G, Turner C. Focal adhesions: transmembrane junctions between the extracellular matrix and the cytoskeleton. Annu Rev Cell Biol. 1988; 4:487-525. PMID: 3058164.
-
Kelly T, Molony L, Burridge K. Purification of two smooth muscle glycoproteins related to integrin. Distribution in cultured chicken embryo fibroblasts. J Biol Chem. 1987 Dec 15; 262(35):17189-99. PMID: 3500174.
-
Burridge K, Molony L, Kelly T. Adhesion plaques: sites of transmembrane interaction between the extracellular matrix and the actin cytoskeleton. J Cell Sci Suppl. 1987; 8:211-29. PMID: 3332661.
-
Burridge K, Kelly T, Connell L. Proteins involved in the attachment of actin to the plasma membrane. Philos Trans R Soc Lond B Biol Sci. 1982 Nov 04; 299(1095):291-9. PMID: 6129663.
-
Burridge K, Kelly T, Mangeat P. Nonerythrocyte spectrins: actin-membrane attachment proteins occurring in many cell types. J Cell Biol. 1982 Nov; 95(2 Pt 1):478-86. PMID: 6183274.
This graph shows the total number of publications by year, by first, middle/unknown, or last author.
To see the data from this visualization as text, click here.
Year | Publications |
---|
1989 | 1 | 1993 | 1 | 1994 | 3 | 1997 | 1 | 1998 | 2 | 1999 | 2 | 2000 | 1 | 2002 | 1 | 2003 | 5 | 2004 | 3 | 2005 | 5 | 2006 | 2 | 2008 | 2 | 2009 | 1 | 2010 | 3 | 2011 | 1 | 2012 | 2 | 2015 | 3 | 2016 | 2 | 2017 | 1 | 2019 | 1 | 2020 | 2 | 2021 | 2 | 2022 | 2 | 2023 | 4 | 2024 | 4 |
To return to the timeline, click here.
|
Kelly Jr's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|